INTRODUCTION

• Invasive fungal infections (IFIs) are an emerging problem worldwide, largely due to increased use of immunosuppressive agents among certain populations (e.g. cancer and transplant patients). Almost 87% of all IFIs are caused by Candida and Aspergillus species.1,2

• Major risk factors for IFIs include neutropenia, haematological malignancies, bone marrow transplantation, prolonged corticosteroid therapy, prolonged stays in intensive care, chemotherapy, HIV infection, invasive medical procedures, and use of immunosuppressive agents, (like Alemrutzumab, Dazluzumab, etc.)3,4

• Recent global estimates suggest that IFIs are responsible for 1.5 million deaths annually and have a mortality rate of around 40%.5 In the United States, the clinical and economic burden of IFIs was reported to be substantial, especially in transplant recipients. Patients with an IFI had, on an average, a 5-fold increase in mortality, an additional 19.2 hospital days, and $55,400 in excess costs compared with patients without an IFI.1

• High mortality rates were also reported from Kingdom of Saudi Arabia (KSA) ranging from 43 to 59%.6 In the year 2012, incidence of IFIs was reported to be 1,95/1000 discharges in KSA.7

• Treatment options for IFIs globally include fucutensone, polyenes (amphotericin), triazoles (fluconazole, itraconazole, posaconazole, voriconazole) and echinocandins (anidulafungin, caspofungin, micafungin).8

• Amphotericin B (AmB) is commonly used for treatment of IFIs. Amphotericin B lipid complex (ABLC) (which is a 1:1 combination of AmB and lipid moiety) is indicated for the treatment of IFIs in patients who are intolerant of conventional AmB therapy, while Liposomal Amphotericin B (L-AmB) is indicated in patients with renal impairment or untolerated toxicity of AmB therapy.4,910

• L-AmB is a unique liposomal formulation of AmB. It is a single bilayer liposomal drug delivery system and has prolonged mean residence time in body making it efficacious even at lower doses. L-AmB indicated in patients with renal impairment or untolerated toxicity of AmB therapy.

• In the United States, the clinical and economic burden of IFIs was reported to be substantial, especially in transplant recipients. Patients with an IFI had, on an average, a 5-fold increase in mortality, an additional 19.2 hospital days, and $55,400 in excess costs compared with patients without an IFI.1

OBJECTIVE

• This study evaluated the budgetary impact of introducing L-AmB versus ABLC (per year) for the treatment of IFIs in King Faisal Specialist Hospital and Research Centre (KFSHRC) in KSA.

METHODOLOGY

A Budget Impact Model (BIM) was developed to understand the economic effect of introduction of L-AmB in KSA.

• Model’s considerations:
  - Model structure and perspective: Microsoft® Excel based model was developed from payer perspective.
  - Model Inputs: Various inputs such as estimated number of patients at KFSHRC treated for IFIs, direct costs based on literature review and experts’ interviews.
  - Model Outputs: The model assessed the change in the hospital budget following the introduction of L-AmB as treatment option in addition to ABLC. These were calculated in the form of two scenarios:
    - Scenario 1 – Current scenario with ABLC only
    - Scenario 2 – Anticipated scenario with L-AmB replacing ABLC as choice of therapy by 100%
  - Sensitivity Analysis: A one-way sensitivity analysis was performed to understand the impact on budget when various model inputs were increased or decreased by 20%.

RESULTS

Introduction of L-AmB at KFSHRC demonstrated cost savings compared to ABLC with total savings of 22.8% (Fig. 1). The reduction in total costs for L-AmB was driven by both lower medication costs and lower adverse event management costs.

Use of L-AmB reduced medication cost by 20.5% while the cost of managing adverse events were 52.7% lower compared to ABLC. L-AmB decreased total medication cost compared to ABLC by reducing the drug acquisition costs by 27.4%, drug administration cost by 2.9% and the vial wastage by 54.4% due to better dosing regimen (Fig. 2).

Adverse events with L-AmB were considerably lower than those with ABLC (Fig. 3). Use of L-AmB lead to 56.9% decrease in nephrotoxicity compared to ABLC, while the relative difference for dialysis, infusion related reactions and hypogammaglobulinaemia ranged between -36.6% and -60.1%.

The sensitivity analysis (Fig. 4) showed that increasing or decreasing the treatment duration and the AE rates by 20% for ABLC and L-AmB had the highest impact on both medication costs and total costs, compared to baseline.

CONCLUSION

• The introduction of L-AmB in the KSA market is expected to be associated with more cost savings as compared to ABLC in management of IFIs.

• The above results are expected to support in communicating the value of the new intervention, which can be critical in informing pricing decisions, supporting discussions with different payers as well as reimbursement and formulary listings decision making processes.

References


Figure 1: Overall cost: scenario 1 (ABLC) vs. scenario 2 (L-AmB)

Fig. 2: Medication cost: scenario 1 (ABLC) vs. scenario 2 (L-AmB)

Fig. 3: Number of adverse events: scenario 1 (ABLC) vs. scenario 2 (L-AmB)

Fig. 4: One-way sensitivity analysis: Total costs

Fig. 5: Anticipated medication cost savings compared to ABLC with total savings of 22.8% (x 1,000 SAR)